306 related articles for article (PubMed ID: 5406970)
1. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
Tissot R; Gaillard JM; Guggisberg M; Gauthier G; De Ajuriaguerra J
Neurol Neurocir Psiquiatr; 1969; 10(1):1-25. PubMed ID: 5406970
[No Abstract] [Full Text] [Related]
2. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
Wajsbort J; Hemli JA; Alfandary I; Yahel M; Siegfried J
Wien Med Wochenschr; 1971 Oct; 121(42):741-5. PubMed ID: 5115985
[No Abstract] [Full Text] [Related]
3. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
Tissot R; de Ajuriaguerra J
Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
[No Abstract] [Full Text] [Related]
4. [Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
Ferel D
Schweiz Med Wochenschr; 1972 Jan; 102(3):88-94. PubMed ID: 4551909
[No Abstract] [Full Text] [Related]
5. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
Court J; Kase JC; Mena I; Palacios E
Rev Med Chil; 1973 Jun; 101(6):452-5. PubMed ID: 4764560
[No Abstract] [Full Text] [Related]
6. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
Steinhäusl H
Wien Med Wochenschr; 1973 Jun; 123(26):433-5. PubMed ID: 4578743
[No Abstract] [Full Text] [Related]
7. [Treatment of Parkinson's disease with L-dopa combined with a decarboxylase inhibitor].
Siegfried J; Klaiber R; Perret E; Ziegler WH
Dtsch Med Wochenschr; 1969 Dec; 94(52):2678-81. PubMed ID: 4903342
[No Abstract] [Full Text] [Related]
8. [Disturbances of catecholamine metabolism (with special reference to dopamine) in the Parkinsonian syndrome].
Tissot R
Presse Med (1893); 1969 Apr; 77(17):617-8. PubMed ID: 5785080
[No Abstract] [Full Text] [Related]
9. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
Andrews CJ; Somerville B
Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
[No Abstract] [Full Text] [Related]
10. Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.
Barbeau A; Mars H; Botez MI; Joubert M
Can Med Assoc J; 1972 Jun; 106(11):1169-74. PubMed ID: 5034697
[TBL] [Abstract][Full Text] [Related]
11. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
Christiani K; Möller WD
Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759
[No Abstract] [Full Text] [Related]
12. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
Görlich J; Markus E
Dtsch Med Wochenschr; 1972 Aug; 97(34):1246-8. PubMed ID: 5048316
[No Abstract] [Full Text] [Related]
13. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
[No Abstract] [Full Text] [Related]
14. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
Lombardo L; de la Garza R; Ivan-Reynoso G
Arch Invest Med (Mex); 1974; 5(2):105-16. PubMed ID: 4433198
[No Abstract] [Full Text] [Related]
15. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
Gehlen W; Eisenlohr JJ
Nervenarzt; 1974 Jan; 45(2):22-9. PubMed ID: 4601993
[No Abstract] [Full Text] [Related]
16. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
Gattringer B; Steinhäusl H
Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
[No Abstract] [Full Text] [Related]
17. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
[No Abstract] [Full Text] [Related]
18. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
Klawans HL; Ringel SP
Confin Neurol; 1973; 35(3):186-92. PubMed ID: 4712885
[No Abstract] [Full Text] [Related]
19. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
Birkmayer W; Linauer W; Mentasti M; Riederer P
Wien Med Wochenschr; 1974 Jun; 124(22):340-4. PubMed ID: 4275492
[No Abstract] [Full Text] [Related]
20. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
Stammler A; Vielhaber K
Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
[No Abstract] [Full Text] [Related]
[Next] [New Search]
